Experimental drug reverses paralysis and vision loss in multiple sclerosis model

edited by Sadie Harley , reviewed by Robert Egan

This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:

Add as preferred source Credit: Pixabay/CC0 Public Domain A drug developed by a UVA Health scientist has not only stopped but reversed paralysis and vision loss in a mouse model of multiple sclerosis. The results are striking because existing MS treatments are designed to reduce future inflammatory attacks, not restore neurological function already lost.

The research is published in the journal Science Translational Medicine .

The drug, Kamuvudine K-9, is a derivative of HIV drugs already approved for use in people. It was developed by Jayakrishna Ambati, MD, founding director of UVA's Center for Advanced Vision Science and the DuPont Guerry III Professor in the UVA School of Medicine's Department of Ophthalmology.